7 years ago

PredictImmune Receives £4.3 Million Grant from Wellcome Trust for Crohn's Disease Biomarker Trial

  • PredictImmune, a Cambridge-based developer of prognostic tools for immune-mediated diseases, has secured £4.3 million in funding from the Wellcome Trust

  • The funds will be used to support a clinical trial for its prognostic biomarker test in Crohn's disease

  • The trial, called PROFILE, is sponsored by Cambridge University Hospital and the University of Cambridge

  • PredictImmune previously raised £4.7 million in Series A funding led by Parkwalk Opportunities Fund with co-investment from Cambridge Enterprise and Wren Capital

  • This funding will be used for commercial development of laboratory services and diagnostic kits for routine use in clinical gastroenterology in Europe and the United States.

      • ProblemHealthcare

      "Crohn's disease, a major form of inflammatory bowel disease, has unpredictable outcomes making it difficult to choose the best treatment option. "

      Solution

      "PredictImmune developed a blood test that predicts the course of a patient's illness using genetic markers, allowing doctors to identify patients who will experience severe, relapsing forms of the disease, leading to better treatment decisions."

      Covered on